Compare INTA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTA | TRVI |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.6B |
| IPO Year | 2021 | 2019 |
| Metric | INTA | TRVI |
|---|---|---|
| Price | $48.02 | $12.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $41.57 | $28.18 |
| AVG Volume (30 Days) | 474.8K | ★ 2.5M |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $577,805,000.00 | N/A |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $15.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.62 | N/A |
| 52 Week Low | $19.01 | $9.82 |
| 52 Week High | $47.93 | $20.22 |
| Indicator | INTA | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 80.94 | 36.64 |
| Support Level | $20.15 | $9.97 |
| Resistance Level | N/A | $13.55 |
| Average True Range (ATR) | 1.60 | 0.68 |
| MACD | 0.94 | 0.12 |
| Stochastic Oscillator | 98.44 | 38.77 |
Intapp Inc is a provider of AI-powered solutions for professional firms in regulated industries. Its vertically tailored solutions are purpose-built for the specialized workflows, complex relationship networks, and professional compliance requirements of accounting, consulting, investment banking, legal, private capital, and real assets firms. By applying Firm AI to core processes and data, Intapp helps partners, dealmakers, and advisors drive firm growth, manage compliance, and improve profitability. Its products include AI & Data Platform, Intapp Celeste and Firm AI, and Intapp Integration Service. The Company operates in accounting, consulting, corporate, investment banking and advisory, and other industries. The Company operates in the UK and the US, with maximum revenue from the US.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.